Novel 4-(trifluoromethyl)isoxazoles and sulfenyl/selanyl phenanthrene derivatives for anti-cancer drug development

Overview

This research program focuses on the design and synthesis of two classes of novel small molecules intended to serve as starting points for new anti-cancer therapeutics. The first class centers on 4-(trifluoromethyl)isoxazoles, a heterocyclic scaffold (a ring structure containing nitrogen and oxygen) known for diverse biological activities. Incorporating a trifluoromethyl group is a well-established medicinal chemistry strategy that can enhance metabolic stability, membrane permeability, and overall biological potency. The second class involves sulfenyl and selanyl phenanthrenes, along with related polycyclic aromatic hydrocarbons and polycyclic heteroaromatics, which are being explored as a new family of bioactive molecules with potential anti-cancer properties. Together, these compound libraries offer a chemistry-driven foundation for oncology drug discovery and lead optimization.

Technical specifications

Key features:

• Novel 4-(trifluoromethyl)isoxazole derivatives synthesized through a chemistry-driven approach combining heterocyclic scaffold design with fluorine-containing functional groups
• Trifluoromethyl substitution intended to improve biological activity, bioavailability, and resistance to metabolic breakdown
• Sulfenyl (sulfur-containing) and selanyl (selenium-containing) phenanthrene derivatives expanding the chemical space of polycyclic aromatic and heteroaromatic candidates
• Polycyclic aromatic hydrocarbon and heteroaromatic variants designed to explore structure-activity relationships across related scaffolds
• Compounds positioned as candidates for further biological evaluation against cancer-relevant targets

Technology readiness level

The work is at an early-stage research and synthesis phase. Novel compounds have been produced using the proposed chemistry-driven synthesis approach, but biological validation, efficacy testing, and preclinical development have not yet been completed. The current readiness level is consistent with early-stage discovery chemistry, with the next steps likely involving biological screening, structure-activity optimization, and target validation before any translational or commercial development can proceed.